Aptevo Therapeutics Inc. filings document the regulatory record of a clinical-stage biotechnology company developing immune-oncology candidates based on ADAPTIR and ADAPTIR-FLEX platforms. Its 8-K reports record clinical updates for mipletamig in acute myeloid leukemia, annual financial results, material agreements, executive and board changes, and other public-company events.
The company’s proxy and registration filings disclose shareholder voting matters, proposed charter and administrative amendments, Nasdaq share-issuance approvals, common-stock financing arrangements, and capital-structure information related to its standby equity purchase agreement. These filings also provide formal context for governance, securities issuance mechanics, and the funding disclosures associated with Aptevo’s oncology pipeline.
Schedule 13G filing for Aptevo Therapeutics Inc. (NASDAQ: APVO) discloses that a group of affiliated Yorkville entities, led by YA II PN, Ltd., now beneficially owns 357,842 common shares, equal to 9.99 % of the outstanding stock. The position consists entirely of shares that the investors have the right to acquire pursuant to a $25 million Standby Equity Purchase Agreement (SEPA) executed on 16 June 2025. The SEPA prohibits Aptevo from issuing additional shares to the group if doing so would push their aggregate ownership above the 9.99 % threshold.
- Voting/Dispositive power: 0 shares sole; 357,842 shares shared.
- Outstanding shares basis: 3,224,156 shares reported by the issuer on 20 June 2025 plus the 357,842 acquisition rights held by YA II.
- Reporting persons: YA II PN, YA Global Investments II (U.S.), Yorkville Advisors Global LP, related GPs, Mark Angelo, and SC-Sigma Global Partners.
Aptevo Therapeutics Inc. (APVO) – Schedule 13G filing dated 25 June 2025
The filing discloses the beneficial ownership position of three reporting persons – Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC – in the common stock of Aptevo Therapeutics.
- Initial position (18 Jun 2025): Under the Securities Purchase Agreement ("SPA") the group could have been deemed to own 82,000 shares, or 9.8 % of the then-outstanding 759,156 shares, with potential future ownership of up to 507,500 shares if two warrants (total 425,500 shares) were exercised and blocker provisions were waived.
- Current position (close of business 25 Jun 2025): The reporting persons now report 0 shares beneficially owned, equating to 0.00 % of the class. The share-count denominator used is 2,864,156 shares (759,156 existing + 2,105,000 newly issued at SPA closing).
- Warrant conditions: Both Intracoastal Warrant 1 (410,000 shares) and Warrant 2 (15,500 shares) remain unexercisable until shareholder approval and are each subject to a 9.99 % ownership blocker.
Key takeaways for investors
- The investors that were previously positioned to own almost 10 % of Aptevo now disclose no beneficial ownership, removing a potential large holder from the register.
- Potential dilution from 425,500 warrant shares remains possible, but only after shareholder approval and subject to the 9.99 % cap.
- No financial performance metrics are included; the filing is limited to ownership disclosure.
Schedule 13G highlights for Aptevo Therapeutics (APVO)
- Reporting persons—Bigger Capital Fund LP, Bigger Capital Fund GP, LLC and Michael Bigger—disclosed beneficial ownership of 285,000 common shares, equal to 9.95 % of the 2,864,156 shares that were outstanding immediately after the company’s June 2025 offering.
- The shares are held with shared voting and dispositive power; none of the reporting persons has sole power over the stock.
- In addition to the common shares, the group holds warrants that could convert into far more equity: (i) 12,875 pre-funded warrant shares (subject to a 9.99 % ownership cap) and (ii) 1,532,364 common-warrant shares (subject to a 4.99 % cap; 1,489,375 of these require shareholder approval before becoming exercisable).
- However, the filing states that as of the close of business on 20 June 2025 the reporting persons sold the common stock (including the pre-funded-warrant shares) and therefore now own <5 % of the company’s outstanding shares.
- Because the warrants cannot currently be exercised beyond the ownership caps, immediate dilution risk is limited, but if caps are waived or shareholder approval is obtained the potential issuance of up to 1.53 million shares represents a material overhang relative to the current float.
- The certification indicates the investment is passive and not intended to influence control.